id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-284598-ksoonwf9	Liu, Shan	Mesenchymal stem cells as a potential therapy for COVID-19	2020-05-04		.txt	text/plain	1716	90	40	The main pathologic features of severe or critical COVID-19 were consistent with acute lung injure (ALI)/acute respiratory distress syndrome (ARDS), characterized by cellular fibromyxoid exudates, extensive pulmonary inflammation, pulmonary edema, and hyaline membrane formation. Mesenchymal stem cells (MSCs) can balance the inflammatory response and has been mentioned to be effective on ALI/ARDS from both infectious and noninfectious causes previously, presenting an important opportunity to be applied to COVID-19. In this commentary, we summarize the clinical trials of MSCs treatments on ALI/ARDS and raise MSCs as a hopefully alternative therapy for severe or critical COVID-19. Clinical application of mesenchymal stem cell-derived extracellular vesicle-based therapeutics for inflammatory lung diseases Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome	./cache/cord-284598-ksoonwf9.txt	./txt/cord-284598-ksoonwf9.txt